Advertisement
Australia markets close in 1 hour 54 minutes

  • ALL ORDS

    7,946.90
    +49.40 (+0.63%)
     

  • ASX 200

    7,677.20
    +48.20 (+0.63%)
     

  • AUD/USD

    0.6613
    +0.0001 (+0.01%)
     

  • OIL

    78.38
    +0.27 (+0.35%)
     

  • GOLD

    2,317.50
    +8.90 (+0.39%)
     

  • Bitcoin AUD

    96,582.10
    +878.55 (+0.92%)
     

  • CMC Crypto 200

    1,327.75
    +50.77 (+3.98%)
     

  • AUD/EUR

    0.6142
    +0.0002 (+0.04%)
     

  • AUD/NZD

    1.1025
    +0.0033 (+0.30%)
     

  • NZX 50

    11,821.55
    -116.53 (-0.98%)
     

  • NASDAQ

    17,890.79
    +349.29 (+1.99%)
     

  • FTSE

    8,213.49
    +41.34 (+0.51%)
     

  • Dow Jones

    38,675.68
    +449.98 (+1.18%)
     

  • DAX

    18,001.60
    +105.10 (+0.59%)
     

  • Hang Seng

    18,466.91
    -9.01 (-0.05%)
     

  • NIKKEI 225

    38,236.07
    -38.03 (-0.10%)
     

Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference

Opthea Limited
·1-min read
Opthea Limited
Opthea Limited

MELBOURNE, Australia and PRINCETON, N.J., April 04, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference and participate in one-on-one investor meetings on April 11, 2024.

23rd Annual Needham Virtual Healthcare Conference Presentation Details:

Date:

Thursday, April 11th

Time:

3:45 p.m. ET

Presenter:

Frederic Guerard, Pharm D, CEO

Webcast Link

Here

 

 

A webcast of the Needham presentation can be accessed under “Events & Presentations” in the Investor Relations section of the Company’s website, www.opthea.com.

ADVERTISEMENT

About Opthea

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea’s lead product candidate, sozinibercept, is being evaluated in two pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610,) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve overall efficacy and deliver superior vision gains compared to the standard-of-care anti-VEGF-A agents. To learn more, visit our website and follow us on X and LinkedIn.

Authorized for release to ASX by Fred Guerard, CEO

Investor Enquiries

PJ Kelleher
LifeSci Advisors, LLC
Email: pkelleher@lifesciadvisors.com
Phone: 617-430-7579

Media:

Silvana Guerci-Lena
NorthStream Global Partners
silvana@nsgpllc.com

Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399, Email: info@opthea.com, Web: www.opthea.com